Tripride 1 Tablets contain Glimepiride 1 mg, Pioglitazone 15 mg, and Metformin Hydrochloride 500 mg in sustained-release form. This triple-drug combination offers complementary mechanisms of action for effective glycaemic control in adults with type 2 diabetes mellitus.

Tripride 1 Tablets combine a sulfonylurea, a thiazolidinedione, and a sustained-release biguanide to address multiple pathophysiological defects associated with type 2 diabetes mellitus. Glimepiride enhances insulin secretion from functioning pancreatic beta cells, Pioglitazone improves insulin sensitivity in peripheral tissues, and Metformin decreases hepatic glucose production while improving peripheral glucose utilization. The sustained-release formulation of Metformin provides improved gastrointestinal tolerability and supports convenient once-daily administration.

Tripride 1 Tablets are indicated for the treatment of Type 2 Diabetes Mellitus (T2DM) in adults whose glycaemic targets are not adequately achieved with diet, exercise, monotherapy, or dual oral antidiabetic therapy. It is used as an adjunct to lifestyle modification for improved long-term glycaemic control.

Tripride 1 Tablets exert their antihyperglycaemic effect through three complementary mechanisms. Glimepiride stimulates insulin secretion from functioning pancreatic beta cells, thereby lowering blood glucose levels. Pioglitazone selectively activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in skeletal muscle, adipose tissue, and the liver by regulating genes involved in glucose and lipid metabolism. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral glucose uptake and utilization. Its sustained-release formulation improves gastrointestinal tolerability while maintaining prolonged glycaemic control.

The recommended initial dosage is one tablet taken orally once daily, or as directed by the treating physician. The dosage should be individualized according to the patient's glycaemic response and overall clinical condition.

Tripride 1 Tablets are contraindicated in patients with renal impairment, metabolic acidosis including diabetic ketoacidosis, and in individuals with known hypersensitivity to Glimepiride, Pioglitazone, Metformin, or any other component of the formulation.